Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Head & Neck Cancer Market Will Quadruple by 2024

By GlobalData | February 3, 2016

The treatment market for head and neck squamous cell carcinoma (head and neck cancer) will expand almost fourfold from $386 million in 2014 to $1.53 billion by 2024, representing a strong Compound Annual Growth Rate (CAGR) of 14.8%, according to research and consulting firm GlobalData.

The company’s latest report* states that the major drivers of this impressive growth, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, include an increase in disease prevalence, and the launch of multiple premium-priced therapies for recurrent and metastatic disease. These will be led by immuno-oncology products including Bristol-Myers Squibb’s Opdivo and Merck & Co.’s Keytruda, which are anticipated to enter the head and neck cancer market in late 2016 and 2017 respectively.

Amy Yip, Ph.D., GlobalData’s Analyst covering Oncology, states that the release of new immuno-oncology agents, particularly immune checkpoint inhibitors, has created much interest of late.

Yip explains: “Monoclonal antibodies targeting programmed cell death 1 (PD-1) receptor or programmed death-ligand 1 (PD-L1), including Opdivo, Keytruda, and durvalumab, have generated much excitement in the medical community, with their promising early data and good patient responses.

“GlobalData expects a high patient uptake for these drugs when they are approved, with Keytruda appearing as the market leader in the head and neck cancer space. This is due to its early launch in first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma, allowing it to garner a larger target patient pool compared with Opdivo, which is anticipated to launch only in the second-line setting.”

As a result, GlobalData forecasts that Keytruda will achieve peak sales in head and neck cancer treatment of almost $500 million by 2024 in the 7MM.

Despite the enthusiasm surrounding upcoming immuno-therapies, which could command an annual cost of therapy in the US of $150,000 in other cancer indications such as melanoma, there are no biomarkers available able to identify how well a given patient will respond to these treatments. 

Yip concludes: “With such a high price tag, a reliable predictive biomarker to aid patient selection and to avoid giving therapeutics to those who are unlikely to respond is highly desirable. Indeed, it would encourage greater uptake in biomarker-positive patients and avoid unnecessary financial burdens for biomarker-negative patients.”

*OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE